Carcinoma, Non-Small-Cell Lung: all 6,641 studies
Page 16 of 67. Open to participants first (1,665), then studies with results posted, then the rest; newest registration first within each.
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsRecruitingNCT04895709Phase 1/2
- Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLCRecruitingNCT04886401
- Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCRecruitingNCT04875585Phase 2
- Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLCRecruitingNCT04865250Phase 2
- Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon)RecruitingNCT04857970
- To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruitingNCT04853342Phase 3
- Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation TreatmentRecruitingNCT04852588Not applicable
- The Research Plan of Taiwan Precision MedicineRecruitingNCT04849481
- Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
- Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung CancerRecruitingNCT04840004Phase 2
- A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR MutationsRecruitingNCT04816838Not applicable
- Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.RecruitingNCT04806412Not applicable
- Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic CancerRecruitingNCT04789486Phase 1/2
- Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung CancerRecruitingNCT04789252
- Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerRecruitingNCT04780568Phase 1
- Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.RecruitingNCT04778839Phase 1
- Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsRecruitingNCT04777994Phase 1
- A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung CancerRecruitingNCT04777175
- The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.RecruitingNCT04777084Phase 2
- Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)Not yet recruitingNCT04772287Phase 3
- Phase I Study of Repotrectinib and Osimertinib in NSCLC PatientsRecruitingNCT04772235Phase 1
- Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationNCT04762459Phase 3
- MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerRecruitingNCT04762199Phase 1
- Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II StudyRecruitingNCT04762030Phase 2
- Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung CancerNot yet recruitingNCT04755738Phase 2
- A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With ChemoradiotherapyRecruitingNCT04749394Phase 2
- Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung CancerRecruitingNCT04743752
- Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.RecruitingNCT04737382Not applicable
- Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung CancerRecruitingNCT04728724Phase 2
- Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung CancerRecruitingNCT04726215Phase 2
- Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.RecruitingNCT04720339Not applicable
- Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based TherapyRecruitingNCT04691817Phase 1/2
- Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruitingNCT04686305Phase 1
- Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)RecruitingNCT04636775
- Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin ToxicityRecruitingNCT04631731Phase 1/2
- Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) PatientsRecruitingNCT04616209Phase 1/2
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerRecruitingNCT04614103Phase 2
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingNCT04613596Phase 2/3
- Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)RecruitingNCT04611867Not applicable
- Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingNCT04606446Phase 2
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)RecruitingNCT04585750Phase 1/2
- Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingNCT04585490Phase 3
- Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesAvailableNCT04566393
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingNCT04557449Phase 1/2
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingNCT04550104Phase 1
- Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLCRecruitingNCT04530708Not applicable
- Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLCRecruitingNCT04530227Phase 2
- SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)RecruitingNCT04527419Not applicable
- A Multicenter Cancer Biospecimen Collection StudyRecruitingNCT04510129
- Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNot yet recruitingNCT04506242Phase 2
- The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic MonitoringRecruitingNCT04499794
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerRecruitingNCT04499053Phase 2
- Prospective Observation of Failure Patterns in NSCLC Treated With ICIsNot yet recruitingNCT04492969
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingNCT04486833Phase 1/2
- Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line ImmunotherapyRecruitingNCT04467801Phase 2
- Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLCRecruitingNCT04467723Phase 1/2
- Efficacy and Safety of CRT, Durvalumab and Surgery for SSTNot yet recruitingNCT04465968Phase 3
- Immunotherapy in Lung Cancer: Treatment After IO Cessation.RecruitingNCT04465942
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNot yet recruitingNCT04455594Phase 2
- SBRT Dose Escalation for Reirradiation of Inoperable Lung LesionsRecruitingNCT04455438Not applicable
- Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersRecruitingNCT04410796Phase 2
- Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective StudyRecruitingNCT04401059Phase 4
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1
- Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line RechallengeRecruitingNCT04335292Phase 2
- Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab MaintenanceRecruitingNCT04332367Phase 2
- Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLCRecruitingNCT04324164
- Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLCRecruitingNCT04324151
- Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLCRecruitingNCT04324125
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingNCT04322890Phase 2
- Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerRecruitingNCT04322617Phase 2/3
- Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON TrialRecruitingNCT04322591
- Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCRecruitingNCT04322578Phase 2
- Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cmRecruitingNCT04317534Phase 2
- A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLCRecruitingNCT04316364Phase 3
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingNCT04302025Phase 2
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2
- Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2RecruitingNCT04297605Phase 1
- Development and Analysis of a Stool Bank for Cancer PatientsEnrolling by invitationNCT04291755
- Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerRecruitingNCT04270591Phase 1/2
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingNCT04267848Phase 3
- Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingNCT04253964Phase 2
- A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsRecruitingNCT04237805Phase 1/2
- LAT for Oligoprogressive NSCLC Treated With First-line OSImertinibRecruitingNCT04216121
- Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung CancerRecruitingNCT04210492Phase 1/2
- Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.RecruitingNCT04202809Phase 2
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingNCT04198766Phase 1/2
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)RecruitingNCT04165798
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingNCT04165070Phase 1/2
- PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung CancerRecruitingNCT04151940Not applicable
- Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid MalignanciesRecruitingNCT04149691Phase 1
- Expanded Access to Ensartinib for Participants With ALK+ NSCLCAvailableNCT04146571
- Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLCRecruitingNCT04136535Phase 2
- BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastAvailableNCT04091295
- Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)RecruitingNCT04040361Phase 2
- Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.RecruitingNCT03992885Phase 3
- Adjuvant Chemotherapy With or Without Intercalated IcotinibNot yet recruitingNCT03983811Not applicable
- Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.RecruitingNCT03958565
- Deciphering Mechanisms Underlying Cancer ImmunogenicityRecruitingNCT03958240Not applicable
- Synapse 3D With Intravascular Indocyanine GreenRecruitingNCT03953144Phase 1/2
- Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their CaregiversRecruitingNCT03948100Not applicable